Скачать или смотреть New Monoclonal Antibody Beyfortus: Protecting Young Children from RSV

In a groundbreaking development, a recent real-world study published in the Journal of Infection reveals that the monoclonal antibody, nirsevimab, offers significant protection against RSV in children under 2 years old. This antibody, marketed as Beyfortus, has been approved in several countries, including the US, and has shown remarkable efficacy in preventing RSV infections.
The study found that children who received nirsevimab had lower RSV infection rates compared to those who didn't. This discovery may lead to discussions on dosing schedules for infants and young children, potentially revolutionizing RSV prevention strategies.
Learn more about this exciting medical advancement and its implications for pediatric healthcare.